GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sunesis Pharmaceuticals Inc (FRA:RYIS) » Definitions » Cyclically Adjusted Price-to-FCF

Sunesis Pharmaceuticals (FRA:RYIS) Cyclically Adjusted Price-to-FCF : (As of May. 25, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Sunesis Pharmaceuticals Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Sunesis Pharmaceuticals Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Sunesis Pharmaceuticals's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sunesis Pharmaceuticals Cyclically Adjusted Price-to-FCF Chart

Sunesis Pharmaceuticals Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Sunesis Pharmaceuticals Quarterly Data
Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Sunesis Pharmaceuticals's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Sunesis Pharmaceuticals's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sunesis Pharmaceuticals's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sunesis Pharmaceuticals's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Sunesis Pharmaceuticals's Cyclically Adjusted Price-to-FCF falls into.



Sunesis Pharmaceuticals Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Sunesis Pharmaceuticals's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2020 is calculated as:

For example, Sunesis Pharmaceuticals's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2020 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Dec. 2020 (Change)*Current CPI (Dec. 2020)
=-0.899/109.8968*109.8968
=-0.899

Current CPI (Dec. 2020) = 109.8968.

Sunesis Pharmaceuticals Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201103 -73.800 94.283 -86.022
201106 -23.873 95.235 -27.548
201109 -75.953 95.727 -87.196
201112 -86.328 95.213 -99.641
201203 -109.984 96.783 -124.887
201206 -72.594 96.819 -82.399
201209 166.672 97.633 187.608
201212 -100.814 96.871 -114.370
201303 -104.600 98.209 -117.048
201306 -100.542 98.518 -112.155
201309 -90.264 98.790 -100.412
201312 -95.703 98.326 -106.965
201403 -107.571 99.695 -118.579
201406 -89.310 100.560 -97.603
201409 -118.902 100.428 -130.113
201412 -77.777 99.070 -86.277
201503 -116.511 99.621 -128.529
201506 -73.859 100.684 -80.617
201509 -84.275 100.392 -92.254
201512 -81.875 99.792 -90.165
201603 -81.542 100.470 -89.192
201606 -71.110 101.688 -76.850
201609 -66.805 101.861 -72.075
201612 -47.829 101.863 -51.601
201703 -52.494 102.862 -56.084
201706 -54.659 103.349 -58.122
201709 -44.860 104.136 -47.342
201712 -17.475 104.011 -18.464
201803 -18.971 105.290 -19.801
201806 -17.961 106.317 -18.566
201809 -15.837 106.507 -16.341
201812 -18.690 105.998 -19.377
201903 -11.201 107.251 -11.477
201906 -10.358 108.070 -10.533
201909 -5.746 108.329 -5.829
201912 -1.058 108.420 -1.072
202003 -5.718 108.902 -5.770
202006 -5.654 108.767 -5.713
202009 -2.768 109.815 -2.770
202012 -0.899 109.897 -0.899

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Sunesis Pharmaceuticals  (FRA:RYIS) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Sunesis Pharmaceuticals Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Sunesis Pharmaceuticals's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Sunesis Pharmaceuticals (FRA:RYIS) Business Description

Traded in Other Exchanges
N/A
Address
395 Oyster Point Boulevard, Suite 400, South San Francisco, CA, USA, 94080
Sunesis Pharmaceuticals Inc is a US-based biopharmaceutical company. It focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The product portfolio of the company includes Vosaroxin which is an anticancer quinolone derivative for the treatment of acute myeloid leukemia (AML). The company's other kinase inhibitor pipeline includes TAK-580, SNS-062, and SNS-229. Further, the firm's activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. The firm derives substantially the majority of revenue from license and collaboration agreements.

Sunesis Pharmaceuticals (FRA:RYIS) Headlines

No Headlines